A genetic mutation that predisposes Ashkenazi Jewish women to ovarian cancer makes them more responsive to chemotherapy, according to a new study. Patients with the BRCA mutation lived about two years longer than patients without the gene, according to the study of 189 Jewish women published in this week’s edition of the Journal of the American Medical Association.
The Archive of the Jewish Telegraphic Agency includes articles published from 1923 to 2008. Archive stories reflect the journalistic standards and practices of the time they were published.
